Neuland Laboratories shares surged 10% on August 6, 2026, after the company reported first-quarter results that surpassed analyst expectations, accompanied by what market watchers described as a strong management commentary.

Neuland Laboratories is an India-based pharmaceutical company listed on Indian stock exchanges. The company is known for its active pharmaceutical ingredients (APIs) and contract manufacturing services, operating in two high-growth segments of the pharmaceutical value chain. India is one of the world's largest suppliers of generic drugs and APIs, and companies with established API and contract manufacturing capabilities have drawn increasing attention as global pharmaceutical supply chains diversify beyond China.

Following the Q1 earnings release, all four analysts who track Neuland Laboratories maintain a "buy" rating on the stock. The consensus estimate of price targets implies an upside potential of approximately 18% from prevailing market levels.

JM Financial holds the highest price target on the street for Neuland Laboratories at ₹25,819 per share.

The strong post-results rally reflects positive market reception to the company's quarterly performance and forward-looking commentary. For investors tracking the Indian pharmaceutical sector, Neuland's results add to a broader pattern of API and contract manufacturing firms reporting robust demand, with analysts watching margin trajectory, capacity utilization, and new contract wins as key indicators of sustained growth.

Source: CNBC-TV18 Markets